Hims & Hers and Novo Nordisk End Feud Over Weight-Loss Drugs

The two companies have reached a deal to sell Novo's popular GLP-1 medicines on Hims & Hers' telehealth platform.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Hims & Hers and Novo Nordisk have ended their eight-month-long public feud over GLP-1 weight-loss drugs. Under the new agreement, Novo will drop its lawsuit against Hims & Hers and start selling its Ozempic and Wegovy brands on the telehealth platform, while Hims & Hers will stop advertising copycat versions of Novo's drugs.

Why it matters

The resolution of this dispute is significant as it allows both companies to move forward and capitalize on the growing demand for weight-loss medications. Novo gains access to Hims & Hers' digital distribution channels, while Hims & Hers can continue offering Novo's branded drugs to patients.

The details

Hims & Hers had previously produced and marketed a compounded version of Wegovy, a move that prompted Novo to pull out of an agreement to sell its products through the telehealth company. Novo then threatened legal action, leading Hims & Hers to withdraw the compounded drug. Under the new deal, Hims & Hers will continue selling Wegovy and Ozempic, but will stop advertising copycat versions of Novo's medications.

  • The feud between the two companies began in June 2025 when Novo pulled out of an agreement to sell its products through Hims & Hers.
  • In February 2026, Novo filed a lawsuit against Hims & Hers over the telehealth company's efforts to produce and market a compounded version of Wegovy.
  • In March 2026, the two companies announced they had reached a deal to end their dispute.

The players

Hims & Hers

A telehealth company that provides online access to various health and wellness products, including prescription medications.

Novo Nordisk

A Danish pharmaceutical company that produces and markets a range of diabetes and weight-loss medications, including the popular GLP-1 drugs Ozempic and Wegovy.

Mike Doustdar

The CEO of Novo Nordisk.

Got photos? Submit your photos here. ›

What they’re saying

“When you want to make an agreement with anyone, you really need to know exactly what that agreement is. I take my time, and then when I do it, more times than not, we do it right.”

— Mike Doustdar, CEO, Novo Nordisk (Bloomberg)

The takeaway

This deal represents a pragmatic compromise between the two companies, allowing them to move past their differences and capitalize on the growing demand for weight-loss medications. It demonstrates the importance of clear communication and alignment of goals when forging strategic partnerships in the healthcare industry.